GotoPER - Physicians' Education Resource
Back to Home
Multimedia

Burst CME™: Future Implications for the Treatment Landscape of Primary Biliary Cholangitis (PBC)

Create AccountAlready Registered? Login Here

Release Date

August 30, 2024

Expiration Date

August 31, 2025

Credits

0.25 CME

Release Date: August 30, 2024

Expiration Date: August 30, 2025

Activity Overview 

This online activity is designed to provide a concise overview of patient-centered care of primary biliary cholangitis (PBC). Long-term management involves monitoring of liver function and common complications of cholestasis. This activity also covers emerging agents being developed to directly control symptoms, including cholestatic pruritus.

Target Audience 

This educational activity is directed toward hepatologists, gastroenterologists, primary care clinicians, NPs, and PAs, nurses, and other HCPs involved in the care of patients with PBC

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss the impact of therapy initiation on the overall burden of PBC
  • Identify the utility of biomarkers in determining biochemical response to PBC therapy
  • Summarize evidence supporting the introduction of second-line therapy for PBC
  • Implement new paradigms for first- and second-line PBC therapy to optimize long-term outcomes
Burst CME™: Future Implications for the Treatment Landscape of Primary Biliary Cholangitis (PBC)

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Ipsen Biopharmaceuticals.

You Also Might Like...

Collaborating Across the Continuum®: Tying the Threads: Screening, Referrals, and Optimized Treatments in MASLD/MASHFree CE/CME

Collaborating Across the Continuum®: Tying the Threads: Screening, Referrals, and Optimized Treatments in MASLD/MASH

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?Free CE/CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical DataFree CE/CME

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Navigating the Adverse Event Landscape in HER2+ GEA TherapyFree CE/CME

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Course

Burst CME™: Future Implications for the Treatment Landscape of Primary Biliary Cholangitis (PBC)

Create Account